3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
376
Neoplasm Metastasis
21
Neoplasms
11
Advanced Breast Cancer
10
Carcinoma, Intraductal, Noninfiltrating
8
Triple Negative Breast Neoplasms
7
Osteoporosis
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
6
Carcinoma, Lobular
5
Prostatic Neoplasms
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Arthralgia
4
Recurrence
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Squamous Cell Carcinoma of Head and Neck
2
Pain
2
Obesity
2
Neoplasms by Site
2
Multiple Endocrine Neoplasia Type 1
2
Infertility
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Interventions
belinostat
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
Nivolumab
1
Mass Spectrometry
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Letrozole
×
Breast
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled